Brief: Kancera Presents Statistical Analysis From The Fractal Study

Novakand Pharma AB

06/02/2024 07:14

Feb 6 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA PRESENTS THE STATISTICAL ANALYSIS OF TOP LINE DATA
FROM
THE FRACTAL STUDY
    * PRIMARY OBJECTIVE WAS MET, BY SHOWING THAT KAND567 WAS
SAFE AND
WELL TOLERATED IN HIGH-RISK ST-ELEVATION MYOCARDIAL INFARCTION
PATIENTS
    * SECONDARY OBJECTIVE WAS MET, BY DEMONSTRATING SIGNALS OF
CARDIO-PROTECTIVE EFFECTS
    * PRIMARY ENDPOINTS CONFIRM A FAVORABLE SAFETY PROFILE IN
STEMI
PATIENTS
    * SECONDARY ENDPOINTS AND IMMUNE MARKERS CONFIRM
PHARMACOLOGICAL
EFFECT AND SUPPORT FOR A MAINTAINED IMMUNE FUNCTION

Source text for Eikon:  ID:nMFN9Tr9hl 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))